Orthocell gets approval from Europe for its regenerative medicine, its shares soar

Sean Gallup/Getty Images

Shares in Orthocell jumped after the medtech gained approval to sell its dental bone and soft tissue regeneration solution in Europe.

The company came out of a trading halt and the shares took off. A short time ago, they were 16% higher at $0.36.

The Perth-based regenerative medicine company announced European regulatory approval for its CelGro collagen medical device.

“This provides a strong foundation for Orthocell to progress additional dental regulatory applications in key markets, such as the US, Japan and Australia,” says Orthocell Managing Director Paul Anderson.

Business Insider Emails & Alerts

Site highlights each day to your inbox.

Follow Business Insider Australia on Facebook, Twitter, LinkedIn, and Instagram.